The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the six months ended June 30, 2025 and June 30, 2024 (in thousands):


	Three Months Ended June 30, 2025		Three Months Ended June 30, 2024		Six Months Ended June 30, 2025		Six Months Ended June 30, 2024
License and other revenue	$	—	$	—	$	15,000	$	—
Less:
OX2R agonist program expenses	(32,681)		(10,300)		(52,774)		(14,952)
LockBody program expenses	(1,765)		(2,096)		(5,183)		(6,266)
Discontinued R&D program expenses	(1,192)		(16,677)		(4,109)		(28,619)
Other R&D expenses:
Personnel expenses¹	(6,077)		(4,901)		(12,379)		(10,500)
Research tax incentives	4,475		5,535		8,734		13,395
Other preclinical and clinical development expenses	(1,386)		(370)		(2,201)		(794)
General and administrative expenses¹	(8,078)		(6,560)		(16,686)		(15,569)
Share-based compensation	(7,949)		(8,611)		(15,832)		(16,765)
Interest and investment income	4,380		3,240		12,270		5,831
Interest expense	(2,884)		(2,525)		(5,761)		(5,054)
Other segment items²	3,592		154		4,618		(1,383)
Income tax expense	(778)		(705)		(2,175)		(1,186)
Consolidated net loss	$	(50,343)	$	(43,816)	$	(76,478)	$	(81,862)

¹ Excludes share-based compensation
² Other segment items includes non-operating income (expenses), net